Similarly, the FLOW trial found a statistically significant 24% reduction in major kidney disease events with weekly 1.0 mg semaglutide among subjects living with T2D and CKD
FDA regulatory failures in enforcing Limits on GLP-1 compounding puts patients at risk
Coadministration of liraglutide and tacrolimus in five kidney transplant recipients resulted in reduced AUC of the latter, but trough levels remained unaltered [26]
Conclusion GLP-1 receptor agonists, such as semaglutide, can play a significant role in weight management by reducing appetite, improving insulin sensitivity, and promoting feelings of fullness
N Engl J Med 1988, 319:15571562
Those taking the drug can experience rapid weight loss, as well as significant side effects